- Home
- TAYD vs PRLD Comparison
TAYD vs PRLD Comparison
Compare TAYD & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TAYD | PRLD |
|---|---|---|
| Founded | 1955 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.0M | 207.5M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TAYD | PRLD |
|---|---|---|
| Price | $70.86 | $2.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $70.00 | $4.67 |
| AVG Volume (30 Days) | 30.9K | ★ 312.0K |
| Earning Date | 03-31-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.24 | ★ 23.21 |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $46,292,725.00 | $12,140,000.00 |
| Revenue This Year | $10.61 | $320.10 |
| Revenue Next Year | $8.56 | $100.00 |
| P/E Ratio | $25.17 | ★ N/A |
| Revenue Growth | 3.84 | ★ 73.43 |
| 52 Week Low | $29.50 | $0.61 |
| 52 Week High | $90.37 | $4.19 |
Technical Indicators
Market Signals| Indicator | TAYD | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 35.72 | 48.78 |
| Support Level | $69.31 | $1.02 |
| Resistance Level | $75.00 | $3.10 |
| Average True Range (ATR) | 4.75 | 0.36 |
| MACD | -2.01 | -0.05 |
| Stochastic Oscillator | 8.10 | 23.29 |
Price Performance
Historical ComparisonAbout TAYD Taylor Devices Inc.
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.